Study identifier:D1444C00147
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A 12-week International, Multicenter, Open Label, Non-comparative Study to Evaluate the Feasibility of Switching any Antipsychotic Treatment to Sustained-release Quetiapine Fumarate (SEROQUEL®) in Patients with Schizophrenia
schizophrenia
Phase 3
No
Seroquel SR
All
550
Interventional
18 Years - 65 Years
Allocation: Non-randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca
AstraZeneca
-
The purpose of this study is to document the clinical benefit of quetiapine (Seroquel) sustained release (SR) after switching from another ongoing antipsychotic treatment, regardless of the reason for the switch. PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.
Location
Location
Vancouver, BC, Canada
Location
Aurora, ON, Canada
Location
Burlington, ON, Canada
Location
Mississauga, ON, Canada
Location
Orleans, ON, Canada
Location
Toronto, ON, Canada
Location
Quebec, Quebec, Canada
Location
Sherbrooke, Quebec, Canada
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.